Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.60 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1189629 | 1.00 | HTR3A (0.60) | HTR3ASLC18A3SIGMAR1JAK3HTR2C | |
| Hydrochloric Acid SCHEMBL3543860 | 0.98 | HTR3A (0.58) | HTR3ASLC18A3SIGMAR1JAK3HTR2C | |
| Hydrochloric Acid SCHEMBL5874037 | 0.98 | HTR3A (0.58) | HTR3ASLC18A3SIGMAR1JAK3HTR2C | |
| SCHEMBL3255979 | 0.90 | HTR3A (0.48) | HTR3A | |
| SCHEMBL373584 | 0.87 | SLC18A3 (0.61) | HTR3ASLC18A3SIGMAR1HTR2CMKNK1 | |
| Hydrochloric Acid SCHEMBL27942946 | 0.85 | SLC18A3 (0.59) | HTR3ASLC18A3SIGMAR1HTR2CMKNK1 | |
| Hydrochloric Acid SCHEMBL31401438 | 0.82 | SLC18A3 (0.52) | HTR3ASLC18A3SIGMAR1HTR2CMKNK1 | |
| SCHEMBL2720916 | 0.82 | CHRNB4 (0.44) | HTR3A | |
| Hydrochloric Acid SCHEMBL8128177 | 0.80 | CHRNB4 (0.43) | HTR3A | |
| Hydrochloric Acid SCHEMBL1742230 | 0.80 | CHRNB4 (0.43) | HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12336991-B2 | Factor XIIA inhibitors | UNIVERSITY OF LEEDS (GB) | 2025-06-24 | — | — | US | disclosed |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2022-09-29 | — | — | US | disclosed |
| EP-1395564-B1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | EP | disclosed |
| US-20050049413-A1 | Quinoline derivatives | MUELLER WERNER (CH) | 2005-03-03 | — | — | US | disclosed |
| US-6818767-B2 | NEUROPEPTIDE Y (NPY) ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS, OR OBESITY | HOFFMANN-LA ROCHE INC. | 2004-11-16 | — | — | US | disclosed |
| EP-1395564-A1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-10 | — | — | EP | disclosed |
| US-20020198194-A1 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
| WO-2002094789-A1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198194-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | HTR3A 133/4885SLC18A3 1402/4885SIGMAR1 633/4885 |
| US-20050049413-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | HTR3A 133/4885SLC18A3 1402/4885SIGMAR1 633/4885 |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | HTR3A 4363/4885SLC18A3 4801/4885SIGMAR1 4596/4885 |
| US-12336991-B2 | Factor XIIA inhibitors | F11, F13B, F12 | HTR3A 4363/4885SLC18A3 4801/4885SIGMAR1 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.